NASDAQ : SLGL
Sol-Gel Technologies Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 68.59 USD (Oct 30, 2026, 3:02 PM EDT) · Market cap 224.56M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 211.89M |
| Enterprise Value | 164.73M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.27M |
| Shares Outstanding | 3.27M |
| Shares Change (YoY) | +4.86% |
| Shares Change (QoQ) | +15.29% |
| Owned by Insiders (%) | 59.73% |
| Owned by Institutions (%) | 12.55% |
| Float | 322,539 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 116.98 |
| Forward PS | 289.62 |
| PB Ratio | 4.65 |
| P/TBV Ratio | 4.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 90.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.37 |
| Quick Ratio | 9.87 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -40.85% |
| Return on Assets (ROA) | -23.87% |
| Return on Invested Capital (ROIC) | -26.67% |
| Return on Capital Employed (ROCE) | -36.39% |
| Weighted Average Cost of Capital (WACC) | 10.54% |
| Revenue Per Employee | $64,107 |
| Profits Per Employee | -$583,464 |
| Employee Count | 28 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.15 |
| 52-Week Price Change | +86.65% |
| 50-Day Moving Average | 68.77 |
| 200-Day Moving Average | 74.01 |
| Relative Strength Index (RSI) | 40.56 |
| Average Volume (20 Days) | 38,855 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 136,264 |
| Short Previous Month | 145,819 |
| Short % of Shares Out | 12.88% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.80M |
| Gross Profit | -14.03M |
| Operating Income | -17.77M |
| Pretax Income | -16.34M |
| Net Income | -16.34M |
| EBITDA | -17.69M |
| EBIT | -17.77M |
| Loss Per Share | -$5.59 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 47.93M |
| Total Debt | 770,000 |
| Net Cash | 47.16M |
| Net Cash Per Share | $14.40 |
| Equity (Book Value) | 48.10M |
| Book Value Per Share | 14.69 |
| Working Capital | 46.15M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -8.54M |
| Capital Expenditures | -50,000 |
| Depreciation & Amortization | 80,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.59M |
| FCF Per Share | -$2.62 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -989.97% |
| Pretax Margin | -910.14% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.86% |
| Shareholder Yield | -4.86% |
| Earnings Yield | -8.64% |
| FCF Yield | -4.09% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $152.50 |
| Price Target Difference | 135.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 0.70% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 5, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 9.46 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |